2023-07-16-世界卫生组织-Immunization_Greece_2023_country_profile_17页_353kb

Summary of Greece Immunization Coverage (WHO/UNICEF - 2022 Revision)

• BCG: Estimated coverage was consistently 100% from 2006 to 2010, officially reported as 100% from 2011 to 2019, and extrapolated as 100% for 2020-2022 with no accepted empirical data for the latter years.

• DTP1: Estimated coverage was consistently 99% from 2006 to 2022. Official coverage was 100% from 2006-2006, with estimates challenged (R- rating) due to reliance on downstream DTP3 data and lack of independent assessment. GOC ratings varied from R to ++.

• DTP3: Estimated coverage was consistently 99% from 2006 to 2021, officially reported as 100% from 2010-2018, and extrapolated as 99% for 2022. High confidence ratings (primarily R+) were noted, though independent assessment was not conducted recently. Estimates from 2013-2021 were supported by national surveys.

• Pol3: Estimated coverage was 99% annually from 2006-2022. Estimated values for 2022 relied on extrapolation. High GOC ratings (R+) were common for earlier years based on survey data.

• HepB Birth Dose: No data estimates (indicated as NA) were available, with administrative and survey data also absent for most years. Official assessments showed 100% coverage in recent years.

• HepB3: Estimated coverage increased from the 95% in 2011 to 96% in 2015-2022. These estimates had ratings from R to ++ depending on data sources and recency.

• Hib3: Coverage reached 94% in 2012, fluctuating between 83% and 99% through 2022. Estimated values had ratings from R to ++.

• RCV1: Derived from MCV1 estimates, coverage generally mirrored MCV1 trends (97-99%), with estimates often rated R or ++.

• RotaC: Coverage estimates were low until 2015 (20%) due to introduction timing and data limitations, remaining around 20% through 2021 with extrapolation for 2022. Ratings were generally R.

• PcV3: PcV was introduced in 2006, reported from 2012 onwards. Coverage began low (~2020) but improved, reaching 32% in 2012 and stabilizing around 96% from 2018-2022. Ratings were R to R++.

• IPV1: Introduction occurred in 2013, with preventive estimates starting 2015. Data were not available from 2013-2014, any from 2015-2020 were extrapolated, and increased to 99% in 2022. GOC ratings were No empirical data in early years, then R.

• MCV1: Coverage reached 99% from 2006 onwards. GOC ratings varied but generally C+ indicated the reliability.

• MCV2: Coverage was relatively lower in early years (~77%) but reached 91-99% by 2014-2022, with GOC ratings indicating various confidence levels.

Data relies heavily on national records and periodic surveys. Extrapolation was common for more recent years (2020-2022) particularly for several vaccines, and independent validation was often lacking.